Astrazeneca Plc reported Revenue growth of 8.63% year on year in the fourth quarter 2024, to $ 58,739.00 millions, this is lower than Astrazeneca Plc's recent average Revenue surge of 104.88%.
Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 74 other companies have achieved higher Revenue growth. While Astrazeneca Plc' s Revenue increase of 8.63% ranks overall at the positon no. 709 in the fourth quarter 2024.
Astrazeneca Plc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Dec 31 2025)
12 Months Ending (Dec 31 2024)
12 Months Ending (Dec 31 2023)
12 Months Ending (Dec 31 2022)
12 Months Ending (Dec 31 2021)
Cumulative Revenue 12 Months Ending
$ 58,739.00
$ 54,073.00
$ 45,811.00
$ 44,351.00
$ 37,417.00
Y / Y Revenue Growth (TTM)
8.63 %
18.03 %
3.29 %
18.53 %
40.58 %
Year on Year Revenue Growth Overall
Ranking
# 706
# 0
# 863
# 0
# 0
Seqeuential Revenue Change (TTM)
8.63 %
18.03 %
3.29 %
18.53 %
40.58 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 806
# 0
# 868
# 0
# 0
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2025 period, Astrazeneca Plc's cumulative twelve months Revenue were $ 58,739 millions, company would post below average annual Revenue growth of 40.58% year on year, if the fiscal year would end at Dec 31 2025. A slow-down in the Astrazeneca Plc's Revenue growth from the 0% growth in Dec 31 2024.
In the Healthcare sector 168 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 706.
With the quarterly Revenue reported in the Dec 31 2025 period, Astrazeneca Plc's cumulative twelve months Revenue were $ 58,739 millions, company would post below average annual Revenue growth of 3.29% year on year, if the fiscal year would end at Dec 31 2025. A slow-down in the Astrazeneca Plc's Revenue growth from the 0% growth in Dec 31 2024.
In the Healthcare sector 168 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 706.
About Astrazeneca Plc Revenue Growth Rates (AZN), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
15.01%